Thomas P Loughran, Jr.


Primary Appointment

F. Palmer Weber-Smithfield Foods Professor of Oncology Research & Professor of Medicine, Medicine- Hematology and Oncology


  • Clinical Fellowship, Oncology, Fred Hutchinson Cancer Research Center
  • MD, Hahnemann Medical College
  • Residency, Thomas Jefferson University Hospital, Philadelphia, PA

Research Disciplines

Bioinformatics and Genomics, Cancer Biology, Computational Biology, Immunology, Molecular Biology, Translational Science

Research Interests

Hematologic malignancies; bone marrow disorders; leukemia; large granular lymphocyte (LGL)

Research Description

Dr. Loughran's current research includes:
current research includes:
⢠R01 grant from the NIHâs National Cancer Institute to identify and characterize the LGL leukemia virus and understand how it might cause leukemia;
⢠NCI RO1 grant to study the pathogenesis of LGL leukemia;
⢠translational research grant from the Leukemia & Lymphoma Society to investigate new treatments for LGL leukemia;
⢠program project grant from the NCI aimed at developing new therapeutics for acute myelogenous leukemia.

Personal Statement

Thomas P. Loughran, Jr., MD, is the director of the University of Virginia Cancer Center, F. Palmer Weber-Smithfield Foods Professor of Oncology Research and Professor of Medicine. From July 2003 to August 2013, he served as the founding director of the Penn State Hershey Cancer Institute and Professor of Medicine at the Penn State College of Medicine. He previously served as program leader of hematologic malignancies at the H. Lee Moffitt Cancer Center and Research Institute at the University of South Florida, associate director of the Bone Marrow Transplant Program at SUNY Health Science Center, and chief of hematology at the Syracuse Veteran's Affairs Medical Center in Syracuse, N.Y. He completed his fellowship in medical oncology at the Fred Hutchinson Cancer Research Center under direction of Nobel Laureate, Dr. E.D. Thomas and remained on faculty there for seven years.
His career as a physician scientist is a testament to translational research beginning with his discovery of large granular lymphocyte (LGL) leukemia. He has published numerous articles in high impact peer-reviewed journals including The New England Journal of Medicine, Annals of Internal Medicine, Lancet, Journal of Clinical Investigation, Journal of Clinical Oncology, and Blood. He and his wife, Kenna, have two daughters, Kathleen and Kelly.


  • Cancer Research Training in Molecular Biology
  • Interdisciplinary Training Program in Immunology
  • Training in the Pharmacological Sciences

Selected Publications


Brammer, J. E., Ballen, K., Sokol, L., Querfeld, C., Nakamura, R., Mishra, A., . . . Loughran, T. (2023). Effective treatment with the selective cytokine inhibitor BNZ-1 reveals the cytokine dependency of T-LGL leukemia. BLOOD, 142(15), 1271-1280. doi:10.1182/blood.2022017643

Ma, H., Loughran, T. P., & Gupta, P. (2023). An analysis of veterans diagnosed with large granular lymphocytic disorders at the national Veteran Affairs Healthcare System. AMERICAN JOURNAL OF HEMATOLOGY, 98(8), E190-E192. doi:10.1002/ajh.26948

Fisher-Wellman, K. H., Kassai, M., Hagen, J. T., Neufer, P. D., Kester, M., Loughran Jr., T. P., . . . Cabot, M. C. (2023). Simultaneous Inhibition of Ceramide Hydrolysis and Glycosylation Synergizes to Corrupt Mitochondrial Respiration and Signal Caspase Driven Cell Death in Drug-Resistant Acute Myeloid Leukemia. CANCERS, 15(6). doi:10.3390/cancers15061883

Barila, G., Grassi, A., Cheon, H., Teramo, A., Calabretto, G., Chahal, J., . . . Zambello, R. (2023). Tγδ LGLL identifies a subset with more symptomatic disease: analysis of an international cohort of 137 patients. BLOOD, 141(9), 1036-1046. doi:10.1182/blood.2021013489


Loughran Jr, T. P., Cohn, W., Bonilla, G., & Anderson, R. T. (2022). Cancer Prevention from the Viewpoint of UVA Comprehensive Cancer Center. CANCER PREVENTION RESEARCH, 15(11), 715-720. doi:10.1158/1940-6207.CAPR-22-0365

Loughran, T. P., Cohn, W., Bonilla, G., & Anderson, R. T. (2022). Cancer Prevention from the Viewpoint of UVA Comprehensive Cancer Center.. Cancer prevention research (Philadelphia, Pa.), OF1-OF6. doi:10.1158/1940-6207.capr-22-0365

Ung, J., Tan, S. -F., Shaw, J., Fox, T., Kester, M., Feith, D., & Loughran, T. J. (2022). Superior Anti-Leukemic Effects of Combined Acid Ceramidase and Bcl-2 Inhibition in Acute Myeloid Leukemia. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 22, S211-S212. Retrieved from

Khokhlatchev, A. V., Sharma, A., Deering, T. G., Shaw, J. J. P., Costa-Pinheiro, P., Golla, U., . . . Kester, M. (2022). Ceramide nanoliposomes augment the efficacy of venetoclax and cytarabine in models of acute myeloid leukemia. FASEB JOURNAL, 36(10). doi:10.1096/fj.202200765R

Cheon, H., Elghawy, O., Shemo, B. C., Feith, D. J., & Loughran, T. P. (2022). LGL leukemia patients exhibit substantial protective humoral responses following SARS-CoV-2 vaccination. EJHAEM, 3(3), 919-923. doi:10.1002/jha2.472

Cheon, H., Xing, J. C., Moosic, K. B., Ung, J., Chan, V. W., Chung, D. S., . . . Loughran Jr, T. P. (2022). Genomic landscape of TCRαβ and TCRγδ T-large granular lymphocyte leukemia. BLOOD, 139(20), 3058-3072. doi:10.1182/blood.2021013164

Baer, C., Kimura, S., Rana, M. S., Kleist, A. B., Flerlage, T., Feith, D. J., . . . Mullighan, C. G. (2022). CCL22 mutations drive natural killer cell lymphoproliferative disease by deregulating microenvironmental crosstalk. NATURE GENETICS, 54(5), 637-+. doi:10.1038/s41588-022-01059-2

Huuhtanen, J., Bhattacharya, D., Lonnberg, T., Kankainen, M., Kerr, C., Theodoropoulos, J., . . . Mustjoki, S. (2022). Single-cell characterization of leukemic and non-leukemic immune repertoires in CD8+ T-cell large granular lymphocytic leukemia. NATURE COMMUNICATIONS, 13(1). doi:10.1038/s41467-022-29173-z

Ung, J., Tan, S. -F., Fox, T. E., Shaw, J. J. P., Vass, L. R., Costa-Pinheiro, P., . . . Loughran, T. P. (2022). Harnessing the power of sphingolipids: Prospects for acute myeloid leukemia. BLOOD REVIEWS, 55. doi:10.1016/j.blre.2022.100950

Mundy-Bosse, B. L., Weigel, C., Wu, Y. -Z., Abdelbaky, S., Youssef, Y., Casas, S. B., . . . Oakes, C. C. (2022). Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma. BLOOD CANCER DISCOVERY, 3(2), 154-169. doi:10.1158/2643-3230.BCD-21-0098

LeBlanc, F. R., Hasanali, Z. S., Stuart, A., Shimko, S., Sharma, K., Leshchenko, V. V., . . . Epner, E. M. (2022). Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma.. Oncotarget, 13, 986-1002. doi:10.18632/oncotarget.28258

Moosic, K. B., Ananth, K., Andrade, F., Feith, D. J., Darrah, E., & Loughran, T. P. (2022). Intersection Between Large Granular Lymphocyte Leukemia and Rheumatoid Arthritis. FRONTIERS IN ONCOLOGY, 12. doi:10.3389/fonc.2022.869205


Fries, C., Evans, A. G., Cheon, H., Korones, D. N., Loughran, T. P. J., & Andolina, J. R. (2022). Allogeneic Bone Marrow Transplant as a Cure for Refractory T-Cell Large Granular Lymphocytic Leukemia in an Adolescent. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 44(6), E960-E963. doi:10.1097/MPH.0000000000002390

Fisher-Wellman, K. H., Hagen, J. T., Kassai, M., Kao, L. -P., Nelson, M. A. M., McLaughlin, K. L., . . . Cabot, M. C. (2022). Alterations in sphingolipid composition and mitochondrial bioenergetics represent synergistic therapeutic vulnerabilities linked to multidrug resistance in leukemia. FASEB JOURNAL, 36(1). doi:10.1096/fj.202101194RRR

Assmann, J. L. J. C., Leon, L. G., Stavast, C. J., van den Bogaerdt, S. E., Schilperoord-Vermeulen, J., Sandberg, Y., . . . Langerak, A. W. (2022). miR-181a is a novel player in the STAT3-mediated survival network of TCRαβ+CD8+T large granular lymphocyte leukemia. LEUKEMIA, 36(4), 983-993. doi:10.1038/s41375-021-01480-2

Golla, U., Ehudin, M. A., Annageldiyev, C., Zeng, Z., Bastihalli Tukaramrao, D., Tarren, A., . . . Sharma, A. (2021). DJ4 Targets the Rho-Associated Protein Kinase Pathway and Attenuates Disease Progression in Preclinical Murine Models of Acute Myeloid Leukemia. CANCERS, 13(19). doi:10.3390/cancers13194889

Olson, T. L., Cheon, H., Xing, J. C., Olson, K. C., Paila, U., Hamele, C. E., . . . Loughran, T. P. J. (2021). Frequent somatic TET2 mutations in chronic NK-LGL leukemia with distinct patterns of cytopenias. BLOOD, 138(8), 662-673. doi:10.1182/blood.2020005831


Cherel, B., Humbert, M., LeBlanc, F. R., Zambello, R., Hamidou, M., Lifermann, F., . . . Lamy, T. (2020). Large Granular Lymphocyte Leukemia and Precapillary Pulmonary Hypertension. CHEST, 158(6), 2602-2609. doi:10.1016/j.chest.2020.07.094

Fox, J., He, M., Loughran, T., Synold, T., & Uthamanthil, R. (2020). Submitting Successful Cancer Center Support Grants (P30) from the Core Perspective.. Journal of biomolecular techniques : JBT, 31(Suppl), S41.

Olson, K. C., Moosic, K. B., Jones, M. K., Larkin, P. M. K., Olson, T. L., Toro, M. F., . . . Loughran, T. P. J. (2020). Large granular lymphocyte leukemia serum and corresponding hematological parameters reveal unique cytokine and sphingolipid biomarkers and associations with STAT3 mutations. CANCER MEDICINE, 9(18), 6533-6549. doi:10.1002/cam4.3246

Mittal, N., Loughran, T. J., & Rivers, A. (2020). T-cell large granular lymphocytic leukemia successfully treated with oral cyclosporine in a child: Case report and review of literature. PEDIATRIC BLOOD & CANCER, 67(12). doi:10.1002/pbc.28487

LeBlanc, F. R., Pearson, J. M., Tan, S. -F., Cheon, H., Xing, J. C., Dunton, W., . . . Loughran, T. P. J. (2020). Sphingosine kinase-2 is overexpressed in large granular lymphocyte leukaemia and promotes survival through Mcl-1. BRITISH JOURNAL OF HAEMATOLOGY, 190(3), 405-417. doi:10.1111/bjh.16530

Cheon, H., Dziewulska, K. H., Moosic, K. B., Olson, K. C., Gru, A. A., Feith, D. J., & Loughran, T. P. J. (2020). Advances in the Diagnosis and Treatment of Large Granular Lymphocytic Leukemia. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 15(2), 103-112. doi:10.1007/s11899-020-00565-6

Wang, T. T., Yang, J., Dighe, S., Schmachtenberg, M. W., Leigh, N. T., Farber, E., . . . Olson, T. L. (2020). Whole Genome Sequencing of Spontaneously Occurring Rat Natural Killer Large Granular Lymphocyte Leukemia Identifies JAK1 Somatic Activating Mutation. CANCERS, 12(1). doi:10.3390/cancers12010126

Annageldiyev, C., Tan, S. -F., Thakur, S., Dhanyamraju, P. K., Ramisetti, S. R., Bhadauria, P., . . . Sharma, A. (2020). The PI3K/AKT Pathway Inhibitor ISC-4 Induces Apoptosis and Inhibits Growth of Leukemia in Preclinical Models of Acute Myeloid Leukemia. FRONTIERS IN ONCOLOGY, 10. doi:10.3389/fonc.2020.00393


Pearson, J. M., Tan, S. -F., Sharma, A., Annageldiyev, C., Fox, T. E., Abad, J. L., . . . Loughran, T. P. (2020). Ceramide Analogue SACLAC Modulates Sphingolipid Levels and MCL-1 Splicing to Induce Apoptosis in Acute Myeloid Leukemia. MOLECULAR CANCER RESEARCH, 18(3), 352-363. doi:10.1158/1541-7786.MCR-19-0619

Nyland, S. B., Feith, D. J., Poss, M., Olson, T. L., Krissinger, D. J., Poiesz, B. J., . . . Loughran, T. P. (2020). Retroviral sero-reactivity in LGL leukaemia patients and family members. BRITISH JOURNAL OF HAEMATOLOGY, 188(4), 522-527. doi:10.1111/bjh.16223

Barth, B. M., Wang, W., Toran, P. T., Fox, T. E., Annageldiyev, C., Ondrasik, R. M., . . . Claxton, D. F. (2019). Sphingolipid metabolism determines the therapeutic efficacy of nanoliposomal ceramide in acute myeloid leukemia. BLOOD ADVANCES, 3(17), 2598-2603. doi:10.1182/bloodadvances.2018021295

Lamy, T., & Loughran, T. P. (2019). Large granular lymphocytic and other rare lymphoid leukemias Preface. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 32(3), 193-195. doi:10.1016/j.beha.2019.09.001

Kao, L. -P., Morad, S. A. F., Davis, T. S., MacDougall, M. R., Kassai, M., Abdelmageed, N., . . . Cabot, M. C. (2019). Chemotherapy selection pressure alters sphingolipid composition and mitochondrial bioenergetics in resistant HL-60 cells. JOURNAL OF LIPID RESEARCH, 60(9), 1590-1602. doi:10.1194/jlr.RA119000251

Li, W., Yang, L., Harris, R. S., Lin, L., Olson, T. L., Hamele, C. E., . . . Poss, M. (2019). Retrovirus insertion site analysis of LGL leukemia patient genomes. BMC MEDICAL GENOMICS, 12. doi:10.1186/s12920-019-0549-9

Moosic, K. B., Paila, U., Olson, K. C., Dziewulska, K., Wang, T. T., Xing, J. C., . . . Olson, T. L. (2019). Genomics of LGL leukemia and select other rare leukemia/lymphomas. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 32(3), 196-206. doi:10.1016/j.beha.2019.06.003

Annageldiyev, C., Gowda, K., Patel, T., Bhattacharya, P., Tan, S. -F., Iyer, S., . . . Sharma, A. (2020). The novel Isatin analog KS99 targets stemness markers in acute myeloid leukemia. HAEMATOLOGICA, 105(3), 687-696. doi:10.3324/haematol.2018.212886

Morad, S. A. F., MacDougall, M. R., Abdelmageed, N., Kao, L. -P., Feith, D. J., Tan, S. -F., . . . Cabot, M. C. (2019). Pivotal role of mitophagy in response of acute myelogenous leukemia to a ceramide-tamoxifen-containing drug regimen. EXPERIMENTAL CELL RESEARCH, 381(2), 256-264. doi:10.1016/j.yexcr.2019.05.021

Tan, S. -F., Dunton, W., Liu, X., Fox, T. E., Morad, S. A. F., Desai, D., . . . Loughran, T. P. (2019). Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-B-dependent P-glycoprotein upregulation. JOURNAL OF LIPID RESEARCH, 60(6), 1078-1086. doi:10.1194/jlr.M091876


Olson, K. C., Larkin, P. M. K., Signorelli, R., Hamele, C. E., Olson, T. L., Conaway, M. R., . . . Loughran, T. P. J. (2018). Vitamin D pathway activation selectively deactivates signal transducer and activator of transcription (STAT) proteins and inflammatory cytokine production in natural killer leukemic large granular lymphocytes. CYTOKINE, 111, 551-562. doi:10.1016/j.cyto.2018.09.016

Wang, T. T., Yang, J., Zhang, Y., Zhang, M., Dubois, S., Conlon, K. C., . . . Loughran, T. P. J. (2019). IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective γ-chain cytokines, decreases leukemic T-cell viability. LEUKEMIA, 33(5), 1243-1255. doi:10.1038/s41375-018-0290-y

Olson, T. L., & Loughran, T. P. J. (2018). Restoring the Long Noncoding RNA MEG3 Indicates a Potential Role for JAK-STAT Signaling in Chronic Myeloid Leukemia. EBIOMEDICINE, 35, 24. doi:10.1016/j.ebiom.2018.08.019

Yang, J., LeBlanc, F. R., Dighe, S. A., Hamele, C. E., Olson, T. L., Feith, D. J., & Loughran, T. P. J. (2018). TRAIL mediates and sustains constitutive NF-κB activation in LGL leukemia. BLOOD, 131(25), 2803-2815. doi:10.1182/blood-2017-09-808816

Dufva, O., Kankainen, M., Kelkka, T., Sekiguchi, N., Awad, S. A., Eldfors, S., . . . Mustjoki, S. (2018). Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. NATURE COMMUNICATIONS, 9. doi:10.1038/s41467-018-03987-2

Kulling, P. M., Olson, K. C., Hamele, C. E., Toro, M. F., Tan, S. -F., Feith, D. J., & Loughran, T. P. J. (2018). Dysregulation of the IFN-γ-STAT1 signaling pathway in a cell line model of large granular lymphocyte leukemia. PLOS ONE, 13(2). doi:10.1371/journal.pone.0193429


Gazitt, T., & Loughran, T. P. J. (2017). Chronic neutropenia in LGL leukemia and rheumatoid arthritis. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 181-186. doi:10.1182/asheducation-2017.1.181

Savola, P., Bruck, O., Olson, T., Kelkka, T., Kauppi, M. J., Kovanen, P. E., . . . Mustjoki, S. (2018). Somatic STAT3 mutations in Felty syndrome: an implication for a common pathogenesis with large granular lymphocyte leukemia. HAEMATOLOGICA, 103(2), 304-312. doi:10.3324/haematol.2017.175729

Kulling, P. M., Olson, K. C., Olson, T. L., Hamele, C. E., Carter, K. N., Feith, D. J., & Loughran, T. P. J. (2018). Calcitriol-mediated reduction in IFN-γ output in T cell large granular lymphocytic leukemia requires vitamin D receptor upregulation. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 177, 140-148. doi:10.1016/j.jsbmb.2017.07.009

Tan, S. -F., Pearson, J. M., Feith, D. J., & Loughran, T. P. J. (2017). The emergence of acid ceramidase as a therapeutic target for acute myeloid leukemia. EXPERT OPINION ON THERAPEUTIC TARGETS, 21(6), 583-590. doi:10.1080/14728222.2017.1322065

Morad, S. A. F., Davis, T. S., MacDougall, M. R., Tan, S. -F., Feith, D. J., Desai, D. H., . . . Cabot, M. G. (2017). Role of P-glycoprotein inhibitors in ceramide-based therapeutics for treatment of cancer. BIOCHEMICAL PHARMACOLOGY, 130, 21-33. doi:10.1016/j.bcp.2017.02.002

Lamy, T., Moignet, A., & Loughran, T. P. J. (2017). LGL leukemia: from pathogenesis to treatment. BLOOD, 129(9), 1082-1094. doi:10.1182/blood-2016-08-692590

Hengst, J. A., Dick, T. E., Sharma, A., Doi, K., Hegde, S., Tan, S. -F., . . . Yun, J. K. (2017). SKI-178: A Multitargeted Inhibitor of Sphingosine Kinase and Microtubule Dynamics Demonstrating Therapeutic Efficacy in Acute Myeloid Leukemia Models.. Cancer translational medicine, 3(4), 109-121. doi:10.4103/ctm.ctm_7_17

Salzberg, A. C., Harris-Becker, A., Popova, E. Y., Keasey, N., Loughran, T. P., Claxton, D. F., & Grigoryev, S. A. (2017). Genome-wide mapping of histone H3K9me2 in acute myeloid leukemia reveals large chromosomal domains associated with massive gene silencing and sites of genome instability. PLOS ONE, 12(3). doi:10.1371/journal.pone.0173723

Salzberg, A. C., Harris-Becker, A., Popova, E. Y., Keasey, N., Loughran, T. P., Claxton, D. F., & Grigoryev, S. A. (2017). Genome-wide mapping of histone H3K9me2 in acute myeloid leukemia reveals large chromosomal domains associated with massive gene silencing and sites of genome instability.. PloS one, 12(3), e0173723. doi:10.1371/journal.pone.0173723


Kulling, P. M., Olson, K. C., Olson, T. L., Feith, D. J., & Loughran, T. P. J. (2017). Vitamin D in hematological disorders and malignancies. EUROPEAN JOURNAL OF HAEMATOLOGY, 98(3), 187-197. doi:10.1111/ejh.12818

Tan, S. -F., Liu, X., Fox, T. E., Barth, B. M., Sharma, A., Turner, S. D., . . . Loughran, T. P. J. (2016). Acid ceramidase is upregulated in AML and represents a novel therapeutic target. ONCOTARGET, 7(50), 83208-83222. doi:10.18632/oncotarget.13079

Olson, K. C., Kulling, P. M., Olson, T. L., Tan, S. -F., Rainbow, R. J., Feith, D. J., & Loughran, T. P. J. (2017). Vitamin D decreases STAT phosphorylation and inflammatory cytokine output in T-LGL leukemia. CANCER BIOLOGY & THERAPY, 18(5), 290-303. doi:10.1080/15384047.2016.1235669

Andersson, E. I., Tanahashi, T., Sekiguchi, N., Gasparini, V. R., Bortoluzzi, S., Kawakami, T., . . . Ishida, F. (2016). High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia. BLOOD, 128(20), 2465-2468. doi:10.1182/blood-2016-06-724856

Morad, S. A. F., Ryan, T. E., Neufer, P. D., Zeczycki, T. N., Davis, T. S., MacDougall, M. R., . . . Cabot, M. C. (2016). Ceramide-tamoxifen regimen targets bioenergetic elements in acute myelogenous leukemia. JOURNAL OF LIPID RESEARCH, 57(7), 1231-1242. doi:10.1194/jlr.M067389

Sang, W., Wang, Y., Zhang, C., Yan, D., Niu, M., Yang, C., . . . Xu, K. (2016). Fludarabine, idarubicin, and cytarabine regimen together with TKI followed by haploidentical hematopoietic stem cell transplantation, a success for relapsed Ph+ acute lymphoblastic leukemia. CLINICAL CASE REPORTS, 4(4), 390-395. doi:10.1002/ccr3.438

Epner, E. M., Saroya, B. S., Hasanali, Z. S., & Loughran, T. P. J. (2016). Combination epigenetic and immunotherapy overcomes resistance to monoclonal antibodies in hematologic malignancies: A new therapeutic approach. EXPERIMENTAL HEMATOLOGY, 44(3), 157-160. doi:10.1016/j.exphem.2015.12.011

Gazitt, T., Lood, C., Sun, X., Feith, D., Ledbetter, J., Starkebaum, G., . . . Elkon, K. B. (2016). Cell-Mediated Neutrophil Lysis-a Mechanism Promoting Hypercitrullination in Rheumatoid Arthritis?. ARTHRITIS & RHEUMATOLOGY, 68. Retrieved from

Sang, W., Sun, C., Zhang, C., Zhang, D., Wang, Y., Xu, L., . . . Xu, K. (2016). MicroRNA-150 negatively regulates the function of CD4+ T cells through AKT3/Bim signaling pathway. CELLULAR IMMUNOLOGY, 306, 35-40. doi:10.1016/j.cellimm.2016.05.007


Sang, W., Wang, Y., Zhang, C., Zhang, D., Sun, C., Niu, M., . . . Xu, K. (2016). MiR-150 impairs inflammatory cytokine production by targeting ARRB-2 after blocking CD28/B7 costimulatory pathway. IMMUNOLOGY LETTERS, 172, 1-10. doi:10.1016/j.imlet.2015.11.001

Sang, W., Zhang, C., Zhang, D., Wang, Y., Sun, C., Niu, M., . . . Xu, K. (2015). MicroRNA-181a, a potential diagnosis marker, alleviates acute graft versus host disease by regulating IFN- production. AMERICAN JOURNAL OF HEMATOLOGY, 90(11), 998-1007. doi:10.1002/ajh.24136

Andersson, E., Kuusanmaki, H., Bortoluzzi, S., Lagstrom, S., Parsons, A., Rajala, H., . . . Mustjoki, S. (2016). Activating somatic mutations outside the SH2-domain of STAT3 in LGL leukemia. LEUKEMIA, 30(5), 1204-1208. doi:10.1038/leu.2015.263

Morad, S. A. F., Davis, T. S., Kester, M., Loughran, T. P. J., & Cabot, M. C. (2015). Dynamics of ceramide generation and metabolism in response to fenretinide - Diversity within and among leukemia. LEUKEMIA RESEARCH, 39(10), 1071-1078. doi:10.1016/j.leukres.2015.06.009

Hasanali, Z. S., Saroya, B. S., Stuart, A., Shimko, S., Evans, J., Shah, M. V., . . . Epner, E. M. (2015). Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia. SCIENCE TRANSLATIONAL MEDICINE, 7(293). doi:10.1126/scitranslmed.aaa5079

Steinway, S. N., Biggs, M. B., Loughran, T. P. J., Papin, J. A., & Albert, R. (2015). Inference of Network Dynamics and Metabolic Interactions in the Gut Microbiome. PLOS COMPUTATIONAL BIOLOGY, 11(6). doi:10.1371/journal.pcbi.1004338

Morad, S. A. F., Tan, S. -F., Feith, D. J., Kester, M., Claxton, D. F., Loughran, T. P. J., . . . Cabot, M. C. (2015). Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia-Impact on enzyme activity and response to cytotoxics. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 1851(7), 919-928. doi:10.1016/j.bbalip.2015.03.001

Murphy, P. W., Brett, L. K., Verla-Tebit, E., Macik, B. G., & Loughran, T. P. J. (2015). Acquired inhibitors to factor VIII and fibrinogen in the setting of T-cell large granular lymphocyte leukemia: a case report and review of the literature. BLOOD COAGULATION & FIBRINOLYSIS, 26(2), 211-213. doi:10.1097/MBC.0000000000000209

Ratan, A., Olson, T. L., Loughran, T. P. J., & Miller, W. (2015). Identification of indels in next-generation sequencing data. BMC BIOINFORMATICS, 16. doi:10.1186/s12859-015-0483-6

Dick, T. E., Hengst, J. A., Fox, T. E., Colledge, A. L., Kale, V. P., Sung, S. -S., . . . Yun, J. K. (2015). The Apoptotic Mechanism of Action of the Sphingosine Kinase 1 Selective Inhibitor SKI-178 in Human Acute Myeloid Leukemia Cell Lines. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 352(3), 494-508. doi:10.1124/jpet.114.219659

Steinway, S. N., Zanudo, J. G. T., Michel, P. J., Feith, D. J., Loughran, T. P., & Albert, R. (2015). Combinatorial interventions inhibit TGFβ-driven epithelial-to-mesenchymal transition and support hybrid cellular phenotypes. NPJ SYSTEMS BIOLOGY AND APPLICATIONS, 1. doi:10.1038/npjsba.2015.14

LeBlanc, F. R., Liu, X., Hengst, J., Fox, T., Calvert, V., Petricoin, E. F. I. I. I., . . . Loughran, T. P. J. (2015). Sphingosine kinase inhibitors decrease viability and induce cell death in natural killer-large granular lymphocyte leukemia. CANCER BIOLOGY & THERAPY, 16(12), 1830-1840. doi:10.1080/15384047.2015.1078949

LeBlanc, F. R., & Loughran, T. P. J. (2015). Large granular lymphocyte leukemia: clinical background, molecular pathogenesis and treatment. EXPERT OPINION ON ORPHAN DRUGS, 3(8), 859-867. doi:10.1517/21678707.2015.1062362

Yan, Y., Olson, T. L., Nyland, S. B., Feith, D. J., & Loughran, T. P. (2015). Emergence of a STAT3 mutated NK clone in LGL leukemia.. Leukemia research reports, 4(1), 4-7. doi:10.1016/j.lrr.2014.12.001


Perzova, R., Graziano, E., Sanghi, S., Welch, C., Benz, P., Abbott, L., . . . Poiesz, B. J. (2015). Increased Seroreactivity to Human T Cell Lymphoma/Leukemia Virus-Related Endogenous Sequence-1 Gag Peptides in Patients with Human T Cell Lymphoma/Leukemia Virus Myelopathy. AIDS RESEARCH AND HUMAN RETROVIRUSES, 31(2), 242-249. doi:10.1089/aid.2014.0171

Hasanali, Z. S., Epner, E. M., Feith, D. J., Loughran, T. P. J., & Sample, C. E. (2014). Vorinostat Downregulates CD30 and Decreases Brentuximab Vedotin Efficacy in Human Lymphocytes. MOLECULAR CANCER THERAPEUTICS, 13(12), 2784-2792. doi:10.1158/1535-7163.MCT-14-0593

Sun, X., Hasanali, Z. S., Chen, A., Zhang, D., Liu, X., Wang, H. -G., . . . Xu, K. (2015). Suberoylanilide hydroxamic acid (SAHA) and cladribine synergistically induce apoptosis in NK-LGL leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 168(3), 371-383. doi:10.1111/bjh.13143

Rajala, H. L. M., Olson, T., Clemente, M. J., Lagstrom, S., Ellonen, P., Lundan, T., . . . Mustjoki, S. (2015). The analysis of clonal diversity and therapy responses using STAT3 mutations as a molecular marker in large granular lymphocytic leukemia. HAEMATOLOGICA, 100(1), 91-99. doi:10.3324/haematol.2014.113142

Cheng, J., Talamo, G., Malysz, J., Ochmann, M., Lamy, T., & Loughran, T. P. (2014). Report of 6 cases of large granular lymphocytic leukemia and plasma cell dyscrasia.. Clinical lymphoma, myeloma & leukemia, 14(5), e169-e172. doi:10.1016/j.clml.2014.04.001

Loughran, T. P. J., Zickl, L., Olson, T. L., Wang, V., Zhang, D., Rajala, H. L. M., . . . Tallman, M. S. (2015). Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). LEUKEMIA, 29(4), 886-894. doi:10.1038/leu.2014.298

Steinway, S. N., Zanudo, J. G. T., Ding, W., Rountree, C. B., Feith, D. J., Loughran, T. P. J., & Albert, R. (2014). Network Modeling of TGFβ Signaling in Hepatocellular Carcinoma Epithelial-to-Mesenchymal Transition Reveals Joint Sonic Hedgehog and Wnt Pathway Activation. CANCER RESEARCH, 74(21), 5963-5977. doi:10.1158/0008-5472.CAN-14-0225

Poullot, E., Zambello, R., Leblanc, F., Bareau, B., De March, E., Roussel, M., . . . Lamy, T. (2014). Chronic natural killer lymphoproliferative disorders: characteristics of an international cohort of 70 patients. ANNALS OF ONCOLOGY, 25(10), 2030-2035. doi:10.1093/annonc/mdu369

Barth, B. M., Keasey, N. R., Wang, X., Shanmugavelandy, S. S., Rampal, R., Hricik, T., . . . Claxton, D. F. (2014). Engraftment of Human Primary Acute Myeloid Leukemia Defined by Integrated Genetic Profiling in NOD/SCID/IL2rγnull Mice for Preclinical Ceramide-Based Therapeutic Evaluation.. Journal of leukemia (Los Angeles, Calif.), 2(3), 146. doi:10.4172/2329-6917.1000146

Doi, K., Liu, Q., Gowda, K., Barth, B. M., Claxton, D., Amin, S., . . . Wang, H. -G. (2014). Maritoclax induces apoptosis in acute myeloid leukemia cells with elevated Mcl-1 expression. CANCER BIOLOGY & THERAPY, 15(8), 1077-1086. doi:10.4161/cbt.29186

Zhang, L., Ramchandren, R., Papenhausen, P., Loughran, T. P., & Sokol, L. (2014). Transformed aggressive γδ-variant T-cell large granular lymphocytic leukemia with acquired copy neutral loss of heterozygosity at 17q11.2q25.3 and additional aberrations. EUROPEAN JOURNAL OF HAEMATOLOGY, 93(3), 260-264. doi:10.1111/ejh.12313

Steinway, S. N., LeBlanc, F., & Loughran, T. P. J. (2014). The pathogenesis and treatment of large granular lymphocyte leukemia. BLOOD REVIEWS, 28(3), 87-94. doi:10.1016/j.blre.2014.02.001

Rajala, H. L. M., Porkka, K., Maciejewski, J. P., Loughran, T. P. J., & Mustjoki, S. (2014). Uncovering the pathogenesis of large granular lymphocytic leukemia-novel STAT3 and STAT5b mutations. ANNALS OF MEDICINE, 46(3), 114-122. doi:10.3109/07853890.2014.882105

Doi, K., Gowda, K., Liu, Q., Lin, J. -M., Sung, S. -S., Dower, C., . . . Wang, H. -G. (2014). Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells. CANCER BIOLOGY & THERAPY, 15(12), 1688-1699. doi:10.4161/15384047.2014.972799


Bedoya-Reina, O. C., Ratan, A., Burhans, R., Kim, H. L., Giardine, B., Riemer, C., . . . Miller, W. (2013). Galaxy tools to study genome diversity. GIGASCIENCE, 2. doi:10.1186/2047-217X-2-17

Perzova, R., Graziano, E., Sanghi, S., Welch, C., Benz, P., Abbott, L., . . . Poiesz, B. J. (2013). Increased seroreactivity to HERV-K10 peptides in patients with HTLV myelopathy. VIROLOGY JOURNAL, 10. doi:10.1186/1743-422X-10-360

Ren, T., Takahashi, Y., Liu, X., Loughran, T. P., Sun, S. -C., Wang, H. -G., & Cheng, H. (2015). HTLV-1 Tax deregulates autophagy by recruiting autophagic molecules into lipid raft microdomains. ONCOGENE, 34(3), 373-384. doi:10.1038/onc.2013.552

Andersson, E. I., Rajala, H. L. M., Eldfors, S., Ellonen, P., Olson, T., Jerez, A., . . . Mustjoki, S. (2013). Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation. BLOOD CANCER JOURNAL, 3. doi:10.1038/bcj.2013.65

Moignet, A., Hasanali, Z., Zambello, R., Pavan, L., Bareau, B., Tournilhac, O., . . . Lamy, T. (2014). Cyclophosphamide as a first-line therapy in LGL leukemia. LEUKEMIA, 28(5), 1134-1136. doi:10.1038/leu.2013.359

Ren, T., Yang, J., Broeg, K., Liu, X., Loughran, T. P. J., & Cheng, H. (2013). Developing an in vitro model of T cell type of large granular lymphocyte leukemia. LEUKEMIA RESEARCH, 37(12), 1737-1743. doi:10.1016/j.leukres.2013.10.002

Mailloux, A. W., Zhang, L., Moscinski, L., Bennett, J. M., Yang, L., Yoder, S. J., . . . Epling-Burnette, P. K. (2013). Fibrosis and Subsequent Cytopenias Are Associated with Basic Fibroblast Growth Factor-Deficient Pluripotent Mesenchymal Stromal Cells in Large Granular Lymphocyte Leukemia. JOURNAL OF IMMUNOLOGY, 191(7), 3578-3593. doi:10.4049/jimmunol.1203424

Jerez, A., Clemente, M. J., Makishima, H., Rajala, H., Gomez-Segui, I., Olson, T., . . . Maciejewski, J. P. (2013). STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. BLOOD, 122(14), 2453-2459. doi:10.1182/blood-2013-04-494930

Aumiller, B. B., Parrott, R., Lengerich, E. J., Dominic, O., Camacho, F., Lehman, E., . . . Loughran, T. P. (2013). Responses to a Theoretically Adapted Clinical Trial Education Session: Faith-Based Sites Versus Rural Work Site Dissemination. JOURNAL OF CANCER EDUCATION, 28(4), 698-708. doi:10.1007/s13187-013-0517-6

Steinway, S. N., & Loughran, T. P. (2013). Targeting IL-15 in large granular lymphocyte leukemia. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 9(5), 405-408. doi:10.1586/ECI.13.28

Rajala, H. L. M., Eldfors, S., Kuusanmaki, H., van Adrichem, A. J., Olson, T., Lagstrom, S., . . . Mustjoki, S. (2013). Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. BLOOD, 121(22), 4541-4550. doi:10.1182/blood-2012-12-474577

LeBlanc, F. R., Hasanali, Z. S., & Loughran, T. P. J. (2013). Does IL-15 have a causative role in large granular lymphocyte leukemia?. IMMUNOTHERAPY, 5(3), 231-234. doi:10.2217/IMT.13.7

Ren, T., Dong, W., Takahashi, Y., Loughran, T. P., Sun, S. -C., Wang, H. -G., & Cheng, H. (2013). HTLV-1 Tax deregulates autophagy in promoting T-cell survival and proliferation.. CANCER RESEARCH, 73(8). doi:10.1158/1538-7445.AM2013-1067

Mailloux, A., Zhang, L., Moscinski, L., Bennett, J., Yang, L., Yoder, S., . . . Epling-Burnette, P. (2013). Pathophysiology of cytopenias in an autoimmune lymphoproliferative disease linked to bone marrow fibrosis. JOURNAL OF IMMUNOLOGY, 190. Retrieved from

Ryland, L. K., Doshi, U. A., Shanmugavelandy, S. S., Fox, T. E., Aliaga, C., Broeg, K., . . . Kester, M. (2013). C6-Ceramide Nanoliposomes Target the Warburg Effect in Chronic Lymphocytic Leukemia. PLOS ONE, 8(12). doi:10.1371/journal.pone.0084648


Watters, R. J., Fox, T. E., Tan, S. -F., Shanmugavelandy, S., Choby, J. E., Broeg, K., . . . Liu, X. (2013). Targeting glucosylceramide synthase synergizes with C6-ceramide nanoliposomes to induce apoptosis in natural killer cell leukemia. LEUKEMIA & LYMPHOMA, 54(6), 1288-1296. doi:10.3109/10428194.2012.752485

Shah, M. V., Barochia, A., & Loughran, T. P. J. (2013). Impact of Genetic Targets on Cancer Therapy in Acute Myelogenous Leukemia. IMPACT OF GENETIC TARGETS ON CANCER THERAPY, 779, 405-437. doi:10.1007/978-1-4614-6176-0_19

Watters, R. J., & Loughran, T. P. J. (2013). Diagnosing large granular lymphocyte leukemia is bloody difficult. LEUKEMIA & LYMPHOMA, 54(2), 438-439. doi:10.3109/10428194.2012.728290

Yang, L., Mailloux, A., Rollison, D. E., Painter, J. S., Maciejewski, J., Paquette, R. L., . . . Epling-Burnette, P. K. (2013). Naive T-cells in myelodysplastic syndrome display intrinsic human telomerase reverse transcriptase (hTERT) deficiency. LEUKEMIA, 27(4), 897-906. doi:10.1038/leu.2012.300

Ren, T., Dong, W., Takahashi, Y., Xiang, D., Yuan, Y., Liu, X., . . . Cheng, H. (2012). HTLV-2 Tax Immortalizes Human CD4+ Memory T Lymphocytes by Oncogenic Activation and Dysregulation of Autophagy. JOURNAL OF BIOLOGICAL CHEMISTRY, 287(41), 34683-34693. doi:10.1074/jbc.M112.377143

Mailloux, A. W., Sugimori, C., Komrokji, R. S., Yang, L., Maciejewski, J. P., Sekeres, M. A., . . . Epling-Burnette, P. K. (2012). Expansion of Effector Memory Regulatory T Cells Represents a Novel Prognostic Factor in Lower Risk Myelodysplastic Syndrome. JOURNAL OF IMMUNOLOGY, 189(6), 3198-3208. doi:10.4049/jimmunol.1200602

Jerez, A., Clemente, M. J., Makishima, H., Koskela, H., LeBlanc, F., Ng, K. P., . . . Maciejewski, J. P. (2012). STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. BLOOD, 120(15), 3048-3057. doi:10.1182/blood-2012-06-435297

LeBlanc, F., Zhang, D., Liu, X., & Loughran, T. P. J. (2012). Large granular lymphocyte leukemia: from dysregulated pathways to therapeutic targets. FUTURE ONCOLOGY, 8(7), 787-801. doi:10.2217/FON.12.75

Koskela, H. L. M., Eldfors, S., Ellonen, P., van Adrichem, A. J., Kuusanmaki, H., Andersson, E. I., . . . Mustjoki, S. (2012). Somatic STAT3 Mutations in Large Granular Lymphocytic Leukemia. NEW ENGLAND JOURNAL OF MEDICINE, 366(20), 1905-1913. doi:10.1056/NEJMoa1114885

Nyland, S. B., Krissinger, D. J., Clemente, M. J., Irby, R. B., Baab, K. T., Jarbadan, N. R., . . . Loughran, T. P. J. (2012). Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: Results of a bone marrow failure consortium study. LEUKEMIA RESEARCH, 36(5), 581-587. doi:10.1016/j.leukres.2012.02.001

Doi, K., Li, R., Sung, S. -S., Wu, H., Liu, Y., Manieri, W., . . . Wang, H. -G. (2012). Discovery of Marinopyrrole A (Maritoclax) as a Selective Mcl-1 Antagonist that Overcomes ABT-737 Resistance by Binding to and Targeting Mcl-1 for Proteasomal Degradation. JOURNAL OF BIOLOGICAL CHEMISTRY, 287(13), 10224-10235. doi:10.1074/jbc.M111.334532

Andersson, E., Eldfors, S., Koskela, H., Ellonen, P., Kallioniemi, O., Porkka, K., . . . Mustjoki, S. (2012). Exome Sequencing of T-LGL Leukemia Patient Revealed ANGPT2 as a Possible Mutational Target. EUROPEAN JOURNAL OF CANCER, 48, S198. doi:10.1016/S0959-8049(12)71458-2

Ren, T., Dong, W., Takahashi, Y., Xiang, D., Yuan, Y., Liu, X., . . . Cheng, H. (2012). Oncogenic properties of tax protein from human T cell leukemia virus type 2. CANCER RESEARCH, 72. doi:10.1158/1538-7445.AM2012-LB-66

Mailloux, A. W., Sugimori, C., Komrokji, R. S., Maciejewski, J. P., Sekeres, M. A., Paquette, R., . . . Epling-Burnette, P. K. (2012). Expansion of effector regulatory T-cells represents a novel and independent prognostic factor marking escape from immune surveillance in Myleodysplastic Syndrome. CANCER RESEARCH, 72. doi:10.1158/1538-7445.AM2012-5417

Hasanali, Z., Sharma, K., Shimko, S., Stuart, A., Liu, X., Epner, E. E., & Loughran, T. P. (2012). Epigenetically induced expression of CD30 in T-PLL: A rationale for the use of brentuximab vedotin. JOURNAL OF CLINICAL ONCOLOGY, 30(15). Retrieved from

Zhang, D., & Loughran, T. P. J. (2012). Large granular lymphocytic leukemia: molecular pathogenesis, clinical manifestations, and treatment. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 652-659. doi:10.1182/asheducation-2012.1.652



Watters, R. J., Wang, H. -G., Sung, S. -S., Loughran, T. P. J., & Liu, X. (2011). Targeting Sphingosine-1-Phosphate Receptors in Cancer. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 11(9), 810-817. Retrieved from

Loughran, T. P., & Wang, H. -G. (2011). Editorial [hot topic: Therapeutic targeting of the sphingolipid "biostat" in hematologic malignancies (guest editors: Thomas P. Loughran and Hong-Gang Wang)].. Anti-cancer agents in medicinal chemistry, 11(9), 780-781. doi:10.2174/187152011797655113

Saadatpour, A., Wang, R. -S., Liao, A., Liu, X., Loughran, T. P., Albert, I., & Albert, R. (2011). Dynamical and Structural Analysis of a T Cell Survival Network Identifies Novel Candidate Therapeutic Targets for Large Granular Lymphocyte Leukemia. PLOS COMPUTATIONAL BIOLOGY, 7(11). doi:10.1371/journal.pcbi.1002267

El-Bayoumy, K., Das, A., Russell, S., Wolfe, S., Jordan, R., Renganathan, K., . . . Somiari, R. (2012). The effect of selenium enrichment on baker's yeast proteome. JOURNAL OF PROTEOMICS, 75(3), 1018-1030. doi:10.1016/j.jprot.2011.10.013

Bai, F., Villagra, A. V., Zou, J., Painter, J. S., Connolly, K., Blaskovich, M. A., . . . Epling-Burnette, P. (2012). Tipifarnib-mediated suppression of T-bet-dependent signaling pathways. CANCER IMMUNOLOGY IMMUNOTHERAPY, 61(4), 523-533. doi:10.1007/s00262-011-1109-0

Clemente, M. J., Wlodarski, M. W., Makishima, H., Viny, A. D., Bretschneider, I., Shaik, M., . . . Maciejewski, J. P. (2011). Clonal drift demonstrates unexpected dynamics of the T-cell repertoire in T-large granular lymphocyte leukemia. BLOOD, 118(16), 4384-4393. doi:10.1182/blood-2011-02-338517

Liao, A., Broeg, K., Fox, T., Tan, S. -F., Watters, R., Shah, M. V., . . . Liu, X. (2011). Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia. BLOOD, 118(10), 2793-2800. doi:10.1182/blood-2011-01-331447

Watters, R. J., Liu, X., & Loughran, T. P. J. (2011). T-cell and natural killer-cell large granular lymphocyte leukemia neoplasias. LEUKEMIA & LYMPHOMA, 52(12), 2217-2225. doi:10.3109/10428194.2011.593276

Barth, B. M., Altinoglu, E. I., Shanmugavelandy, S. S., Kaiser, J. M., Crespo-Gonzalez, D., DiVittore, N. A., . . . Kester, M. (2011). Targeted Indocyanine-Green-Loaded Calcium Phosphosilicate Nanoparticles for In Vivo Photodynamic Therapy of Leukemia. ACS NANO, 5(7), 5325-5337. doi:10.1021/nn2005766

Liu, X., & Loughran, T. P. J. (2011). The spectrum of large granular lymphocyte leukemia and Felty's syndrome. CURRENT OPINION IN HEMATOLOGY, 18(4), 254-259. doi:10.1097/MOH.0b013e32834760fb

Yu, J., Mitsui, T., Wei, M., Mao, H., Butchar, J. P., Shah, M. V., . . . Caligiuri, M. A. (2011). NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human. JOURNAL OF CLINICAL INVESTIGATION, 121(4), 1456-1470. doi:10.1172/JCI43242

Zhang, R., & Loughran, T. P. J. (2011). Off-target effects of tyrosine kinase inhibitors: Beauty or the Beast?. LEUKEMIA & LYMPHOMA, 52(4), 556-557. doi:10.3109/10428194.2011.560694

Ryland, L. K., Fox, T. E., Liu, X., Loughran, T. P., & Kester, M. (2011). Dysregulation of sphingolipid metabolism in cancer. CANCER BIOLOGY & THERAPY, 11(2), 138-149. doi:10.4161/cbt.11.2.14624

Loughran, T. P. J., & Wang, H. -G. (2011). Therapeutic Targeting of the Sphingolipid "Biostat" in Hematologic Malignancies. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 11(9), 780-781. Retrieved from

Ren, T., Liu, X., Loughran, T. P., & Cheng, H. (2011). Developing T-LGL leukemia model for targeted therapy. CANCER RESEARCH, 71. doi:10.1158/1538-7445.AM2011-4304

Campbell, C., Zhang, R., Haley, J. S., Liu, X., Loughran, T., Schell, T. D., . . . Thakar, J. (2011). Why do CD8+T cells become indifferent to tumors: a dynamic modeling approach. FRONTIERS IN PHYSIOLOGY, 2. doi:10.3389/fphys.2011.00032

Watters, R. J., Liu, X., Fox, T. E., Kester, M., & Loughran, T. P. (2011). Targeting the sphingolipid pathway in NK large granular lymphocyte leukemia. CANCER RESEARCH, 71. doi:10.1158/1538-7445.AM2011-4302

Takahashi, Y., Meyerkord, C. L., Hori, T., Runkle, K., Fox, T. E., Kester, M., . . . Wang, H. -G. (2011). Bif-1 regulates Atg9 trafficking by mediating the fission of Golgi membranes during autophagy. AUTOPHAGY, 7(1), 61-73. doi:10.4161/auto.7.1.14015


Lamy, T., & Loughran, T. P. J. (2011). How I treat LGL leukemia. BLOOD, 117(10), 2764-2774. doi:10.1182/blood-2010-07-296962

Talamo, G., Farooq, U., Zangari, M., Liao, J., Dolloff, N. G., Loughran, T. P., & Epner, E. (2010). Beyond the CRAB symptoms: a study of presenting clinical manifestations of multiple myeloma.. Clinical lymphoma, myeloma & leukemia, 10(6), 464-468. doi:10.3816/clml.2010.n.080

Iqbal, J., Weisenburger, D. D., Chowdhury, A., Tsai, M. Y., Srivastava, G., Greiner, T. C., . . . Chan, W. C. (2011). Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic γδ T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro. LEUKEMIA, 25(2), 348-358. doi:10.1038/leu.2010.255

Liu, X., Ryland, L., Yang, J., Liao, A., Aliaga, C., Watts, R., . . . Loughran, T. P. J. (2010). Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia. BLOOD, 116(20), 4192-4201. doi:10.1182/blood-2010-02-271080

Epling-Burnette, P. K., & Loughran, T. P. J. (2010). Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 19(5), 689-698. doi:10.1517/13543781003801076

Abbi, K. K. S., Rizvi, S. M., Sivik, J., Thyagarajan, S., Loughran, T., & Drabick, J. J. (2010). Guillain-Barre syndrome after use of alemtuzumab (Campath) in a patient with T-cell prolymphocytic leukemia: A case report and review of the literature. LEUKEMIA RESEARCH, 34(7), E154-E156. doi:10.1016/j.leukres.2010.02.036

Sekeres, M. A., List, A. F., Cuthbertson, D., Paquette, R., Ganetsky, R., Latham, D., . . . Maciejewski, J. P. (2010). Phase I Combination Trial of Lenalidomide and Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes. JOURNAL OF CLINICAL ONCOLOGY, 28(13), 2253-2258. doi:10.1200/JCO.2009.26.0745

Pastor, D. M., Eggers, A. D., Drabick, J. J., Loughran, T. P., Bayerl, M. G., & Shope, T. R. (2010). Retroperitoneal Diffuse Large B-Cell Lymphoma Presenting As Pseudoachalasia. JOURNAL OF CLINICAL ONCOLOGY, 28(12), E184-E187. doi:10.1200/JCO.2009.25.8715

Talamo, G., Barochia, A., Zangari, M., & Loughran, T. P. (2010). Multiple myeloma presenting as CEA-producing rectal cancer.. Rare tumors, 2(1), e4. doi:10.4081/rt.2010.e4

Abbi, K. K., Wagner, H., Drabick, J. J., Loughran, T. P., & Talamo, G. (2010). The role of radiation therapy for multiple myeloma in the era of novel agents. JOURNAL OF CLINICAL ONCOLOGY, 28(15). doi:10.1200/jco.2010.28.15_suppl.e18557

Thomas, A., Perzova, R., Abbott, L., Benz, P., Poiesz, M. J., Dube, S., . . . Poiesz, B. J. (2010). LGL Leukemia and HTLV. AIDS RESEARCH AND HUMAN RETROVIRUSES, 26(1), 33-40. doi:10.1089/aid.2009.0124

Wozney, J. L., Damluji, A. A., Ahmed, F., Zangari, M., Loughran, T. P. J., & Talamo, G. (2010). Estimation of Daily Proteinuria in Patients with Multiple Myeloma by Using the Protein-to-Creatinine Ratio in Random Urine Samples. ACTA HAEMATOLOGICA, 123(4), 226-229. doi:10.1159/000313448